Navigation Links
Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint

tudy (Study 903) were mild to moderate gastrointestinal events and dizziness. Moderate to severe adverse events occurring in more than 5 percent of patients receiving Viread included rash (rash, pruritis, maculopapular rash, urticaria, vesiculobullous rash and pustular rash), headache, pain, diarrhea, depression, back pain, fever, nausea, abdominal pain, asthenia (weakness) and anxiety. In another pivotal study (Study 907), less than 1 percent of patients discontinued participation because of gastrointestinal events.

It is important for patients to be aware that anti-HIV medicines including Viread do not cure HIV infection or AIDS and do not reduce the risk of transmitting HIV to others. Full prescribing information is available at www.GileadHIV.com.

The parent compound of Viread was discovered through a collaborative research effort between Dr. Antonin Holy, Institute for Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic (IOCB) in Prague and Dr. Erik DeClercq, Rega Institute for Medical Research, Katholic University in Leuven, Belgium.

About Hepsera

Hepsera, a nucleotide analogue for the treatment of chronic hepatitis B, works by inhibiting HBV DNA polymerase, an enzyme involved in the replication of the virus in the body.

In the United States, Hepsera is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.

The adverse reactions considered at least possibly related to treatment reported in 3 percent or greater of patients in the first 48 weeks in Hepsera pivotal clinical studies were asthenia, headache, abdominal pain, nausea, flatulence, diarrhea and dyspepsia. With extended treatment, mild to moderate increases in serum creatinine were observed uncommonly in patients with chronic hepatitis B and compensated liver disease treated
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)... BRIDGEWATER, N.J. , Oct. 20, 2014 ... delivery technology designed for patients with Type 2 diabetes, ... Health Supply Chain Excellence Award. The award was presented ... Conference in Columbus, Ohio . ... recipients are judged across a variety of metrics specifically ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
(Date:10/20/2014)... 2014 hc1.com today announced the ... solution that enables healthcare organizations of all sizes ... customer relationship management (“CRM”) solution. , Designed from ... of the healthcare industry, the hc1 Healthcare Relationship ... patients by combining healthcare CRM, HIPAA-compliant collaboration, and ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Principle ... years, takes pride in manufacturing top-of-the-line absorbent products. ... image of its most popular brand, Tranquility® Premium Protection ... created a new website, gave its packaging a new ... bring the brand message to the public. , The ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... 2014 Unveiled at the Sept. 18 board ... conservatively estimates member hospital ROI on membership dues at 12.5. ... Center provides $12.50 in value to member hospitals. The calculation ... Member Dues)/Member Dues. , “This is the first time ... we think the methodology is really sound,” said Bill ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Sam Smith as the new Chief Executive Officer of the international ... the International Board of Directors on Tuesday. , ... ... the unanimous confirmation of Sam Smith as the new Chief Executive ...
... Healthcare IT provider grows its operations in the Middle East , ... Systems Corporation (NYSE: PER ) ( www.perotsystems.com ) today ... to manage the pilot deployment of VistA - an open source ... a clinic in the capital, Amman. , ...
... EMPHYSEMA AT RISK FOR OSTEOPOROSIS , New research shows ... includes emphysema and chronic bronchitis, may also be at ... scans and pulmonary function tests on 65 male patients ... compare vertebral bone density with percentage of low attenuation ...
... D. England, MD, Professor and Chairman of Neurology at ... is the principal investigator of two studies recommending ... nerve disorder that to this time had few evidence-based ... two separate papers in the December 3, 2008 online ...
... The American Society of Hematology (ASH) will host its ... Marriott on Thursday, December 4, 2008, beginning at 8:00 ... hematology, the biological sciences, and medical research, is held ... year, students will have the opportunity to explore research ...
... N.J., Dec. 3 MedQuist Inc. (Nasdaq: MEDQ ... world, is pleased to announce the positive resolution of several ... Resolution of the DOJ Investigation , ... an administrative HIPAA subpoena for documents from the United States ...
Cached Medicine News:Health News:New CEO Takes Helm at Mercy Ships 2Health News:New CEO Takes Helm at Mercy Ships 3Health News:Perot Systems Awarded Contract to Implement Health Information System in Kingdom of Jordan 2Health News:Perot Systems Awarded Contract to Implement Health Information System in Kingdom of Jordan 3Health News:Journal CHEST: December highlighted studies 2Health News:LSUHSC's England leads development of new testing guidelines for common nerve disorder 2Health News:ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6
Antiseptic - Antibacterial Sudsing Cleanser...
... This requiring no water for ... hand hygiene to physically clean ... is either not an option ... allows you to return to ...
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... Scrub Care® Brand soaps, emulsions, washes ... ultimate in healthy skin care, helping ... skin healthy and soft even with ... not contain petroleum-based substances that can ...
Medicine Products: